Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02440789 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
A Phase 1 study of HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 10
- Study locations
NCT02440789 is a Phase 1 study of HIV-1-infection that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 32 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT02440789, a Phase 1 study of HIV-1-infection, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART. The investigators wanted to learn whether sirolimus decreases inflammation and immune activation in the body; whether sirolimus changes the level of HIV in the participants' blood; and how sirolimus interacts with ART in the blood. Sirolimus is approved by the Food and Drug Administration (FDA) to prevent organ rejection in patients aged 13 years and older receiving kidney transplants. Sirolimus had also been used for the prevention of complications after stem cell transplants and as a treatment for certain kinds of cancers in HIV-infected patients.
Conditions Studied
Interventions
- DRUG Sirolimus
Study Locations (10)
New York
- Weill Cornell Uptown CRS (7803) - New York
- 31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS - Rochester
California
- 801 University of California, San Francisco HIV/AIDS CRS - San Francisco
District of Columbia
- Whitman Walker Health CRS (31791) - Washington D.C.
Florida
- Univ. of Miami AIDS CRS (901) - Miami
Georgia
- The Ponce de Leon Center CRS (5802) - Atlanta
Missouri
- Washington University CRS (2101) - St Louis
Ohio
- Univ. of Cincinnati CRS (2401) - Cincinnati
Texas
- Houston AIDS Research Team CRS (31473) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-12-21 |
| Est. Completion | 2018-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02440789
The ClinicalTrials.gov registry entry for NCT02440789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.
NCT02440789 reports 10 study locations spanning 9 distinct geographic areas - top geographies include New York, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02440789 about?
NCT02440789 is a clinical study titled "Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)". The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART. The investigators wanted to learn whether sirolimus decreases inflammation and immune activation in the body; whether sirolimus changes the level of HIV in ...
What is the current status of trial NCT02440789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-12-21. Estimated completion is 2018-02-01.
What conditions does trial NCT02440789 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT02440789?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT02440789?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02440789 being conducted?
This trial has 10 study locations across California, District of Columbia, Florida, Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
RECRUITING · Phase 1
-
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
RECRUITING · Phase 1
-
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
RECRUITING · Phase 1
-
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
RECRUITING · Phase 1
-
Safety Study of MucoCept-CVN
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.